(STE) STERIS - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: IE00BFY8C754

STE: Sterilizers, Cleaning, Chemicals, Equipment, Sterilants, Services

STERIS plc (NYSE:STE) is a global leader in infection prevention, serving as a critical player in maintaining healthcare safety and efficiency. Their operations span three key segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences, each tailored to meet specific industry needs.

The Healthcare segment is integral to sterile processing departments, offering a range of products from cleaning chemistries to capital equipment like sterilizers and surgical equipment. Their comprehensive services include installation, maintenance, and repair, ensuring healthcare facilities operate seamlessly. This segment underscores STERISs commitment to reliability and innovation in patient care environments.

The AST segment specializes in contract sterilization and testing services, supported by a network of state-of-the-art facilities. They also provide sterilization equipment to medical device manufacturers and research institutions, highlighting their role in ensuring product safety and compliance in the medical and pharmaceutical sectors.

The Life Sciences segment delivers consumable products and services crucial for cleanroom environments, including high-purity water and steam generators. Their offerings support pharmaceutical manufacturing, emphasizing the importance of contamination control and sterility in research and production settings.

With a market cap of over $21.5 billion, STERIS demonstrates financial stability and investor confidence. While the current P/E ratio reflects its premium valuation, the forward P/E suggests expectations of robust growth. This aligns with global trends towards increased healthcare spending and the demand for infection control solutions, positioning STERIS as a strategic long-term investment in a growing industry.

Investors and fund managers should recognize STERISs role in critical healthcare infrastructure, underpinned by a history of reliability and customer-centric innovation. Their diverse offerings and commitment to quality position them as a resilient player in the healthcare equipment sector.

Additional Sources for STE Stock

STE Stock Overview

Market Cap in USD 22,819m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Equipment
IPO / Inception 1992-06-01

STE Stock Ratings

Growth 5y 43.1%
Fundamental 52.3%
Dividend 56.7%
Rel. Strength Industry -3.1
Analysts 3.89/5
Fair Price Momentum 225.26 USD
Fair Price DCF 176.72 USD

STE Dividends

Dividend Yield 12m 0.74%
Yield on Cost 5y 1.27%
Annual Growth 5y 7.20%
Payout Consistency 96.9%

STE Growth Ratios

Growth Correlation 3m 80.6%
Growth Correlation 12m -5.8%
Growth Correlation 5y 63.2%
CAGR 5y 11.81%
CAGR/Max DD 5y 0.33
Sharpe Ratio 12m -0.25
Alpha -6.11
Beta 0.03
Volatility 20.20%
Current Volume 858.9k
Average Volume 20d 427.9k
What is the price of STE stocks?
As of March 13, 2025, the stock is trading at USD 228.06 with a total of 858,866 shares traded.
Over the past week, the price has changed by +1.00%, over one month by +2.10%, over three months by +8.80% and over the past year by -1.76%.
Is STERIS a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, STERIS (NYSE:STE) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 52.27 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of STE as of March 2025 is 225.26. This means that STE is currently overvalued and has a potential downside of -1.23%.
Is STE a buy, sell or hold?
STERIS has received a consensus analysts rating of 3.89. Therefor, it is recommend to buy STE.
  • Strong Buy: 3
  • Buy: 2
  • Hold: 4
  • Sell: 0
  • Strong Sell: 0
What are the forecast for STE stock price target?
According to ValueRays Forecast Model, STE STERIS will be worth about 243.3 in March 2026. The stock is currently trading at 228.06. This means that the stock has a potential upside of +6.67%.
Issuer Forecast Upside
Wallstreet Target Price 250.1 9.7%
Analysts Target Price 248.3 8.9%
ValueRay Target Price 243.3 6.7%